SCHEMBL2551441

SCHEMBL2551441

C[C@@H](O)[C@H](NC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 4/20 0.54
KMT2A Q03164 2/20 0.51
MDM4 O15151 2/20 0.51
TP53 P04637 2/20 0.51
EPHX2 P34913 1/20 0.48
PIN1 Q13526 1/20 0.48
MDM2 Q00987 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7822425 1.00 CASP3 (0.54) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL31610887 1.00 CASP3 (0.54) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL29908073 1.00 CASP3 (0.54) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL29352152 1.00 CASP3 (0.54) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL1486191 1.00 CASP3 (0.54) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL119400 1.00 CASP3 (0.54) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL1486209 1.00 CASP3 (0.54) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL29477078 1.00 CASP3 (0.54) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL30147576 1.00 CASP3 (0.54) CASP3KMT2AMDM4TP53EPHX2
SCHEMBL27843401 1.00 CASP3 (0.54) CASP3KMT2AMDM4TP53EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110627686-A Synthesis method of fluorenylmethyloxycarbonyl-O-trityl-L-threonine 上海吉奉生物科技有限公司 2019-12-31 CN claimed
EP-3473249-A1 CROSSLINKABLE DENDRIMERS Wayne State University (US) 2019-04-24 EP claimed
CN-108373496-A Inoxidizability polypeptide GTMGAVGPRG and preparation method thereof 安徽工程大学 2018-08-07 CN claimed
US-20170028075-A1 INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES Ashvattha Therapeutics, Inc. 2017-02-02 US claimed
US-9526794-B2 Injectable dendrimer hydrogel nanoparticles WAYNE STATE UNIVERSITY (US) 2016-12-27 US claimed
US-20130136697-A1 INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES NATIONAL INSTITUTES OF HEALTH (US) 2013-05-30 US claimed
EP-2552458-A1 INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES Wayne State University (US) 2013-02-06 EP claimed
WO-2011123591-A1 INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES WAYNE STATE UNIVERSITY (US) 2011-10-06 WO claimed
CN-100590068-C Method for preparing primary amine carbon nano tube UNIV TONGJI 2010-02-17 CN claimed
CN-101177259-A Method for preparing primary amine carbon nano tube UNIV TONGJI (CN) 2008-05-14 CN claimed
CN-1490330-A Production of acetooxdralpeptide 上海子能高科股份有限公司 2004-04-21 CN claimed
US-20260116923-A1 CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS MERCK SHARP & DOHME LLC (US) 2026-04-30 US disclosed
EP-4540267-B1 CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA MERCK SHARP & DOHME LLC (US) 2026-04-15 EP disclosed
US-20250152658-A1 CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA MERCK SHARP & DOHME LLC (US) 2025-05-15 US disclosed
US-20230406885-A1 CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA MERCK SHARP & DOHME LLC (US) 2023-12-21 US disclosed
CN-101177259-A Method for preparing primary amine carbon nano tube UNIV TONGJI (CN) 2008-05-14 CN disclosed
EP-1423414-A4 NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME CUBIST PHARM INC (US) 2005-11-30 EP disclosed
EP-1423414-A1 NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME Cubist Pharmaceuticals, Inc. (US) 2004-06-02 EP disclosed
CN-1490330-A Production of acetooxdralpeptide 上海子能高科股份有限公司 2004-04-21 CN disclosed
WO-2003014147-A1 NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME CUBIST PHARMACEUTICALS, INC. (US) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230406885-A1 CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA IL1A, IL1B, IL1R1 CASP3 822/4885KMT2A 4625/4885MDM4 4837/4885
US-20170028075-A1 INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES PAM, UACA, FLT1 CASP3 1763/4885KMT2A 2126/4885MDM4 3299/4885
US-20260116923-A1 CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS IL1A, IL1B, IL1RN CASP3 693/4885KMT2A 3953/4885MDM4 4722/4885
US-20130136697-A1 INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES UACA, PAM, JAK3 CASP3 1280/4885KMT2A 2985/4885MDM4 3016/4885
US-20250152658-A1 CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA IL1R1, IL1A, IL1B CASP3 826/4885KMT2A 4844/4885MDM4 4741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.